RecruitingNCT02744677

COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction

Edwards LifesciencesMultiple US sitesView on ClinicalTrials.gov

AI Description

This study will demonstrate the safety and effectiveness of the Edwards Lifesciences SAPIEN 3/SAPIEN 3 Ultra RESILIA Transcatheter Heart Valve (THV) Systems in subjects with a dysfunctional right ventricular outflow tract (RVOT) conduit or previously implanted valve in the pulmonic position with a clinical indication for intervention.

Report inaccurate information

Who can join
child, adult, older adult
Participants
108
Expected completion
2031-06
Funded by
industry

Conditions studied

Complex Congenital Heart Defect, Dysfunctional RVOT Conduit, Pulmonary Valve Degeneration, Pulmonary Valve Insufficiency

What is being tested

  • DEVICE: SAPIEN 3 THV
  • DEVICE: SAPIEN 3 Ultra RESILIA THV
  • DEVICE: SAPIEN 3/SAPIEN 3 Ultra RESILIA THV

What it measures

  • THV dysfunction, Defined as a non-hierarchical composite of: RVOT reintervention, Moderate or greater total pulmonary regurgitation (PR) via Transthoracic Echocardiography (TTE), Mean RVOT gradient \> 40 mmHg via TTE, 1 year

Centers Participating

These centers are participating in this study. Reach out to them directly to learn more.

Data Sources and Methodology

Registry entry updated 2026-07-23

Deciding whether to join a study is your choice, and you can ask a study team questions before you decide anything.

If you would rather we did it with you, call us on (656) 206-4686.